Semax Dosage: What the Evidence Supports (Intranasal vs Injection)

Search for Semax and you will find confident dosing charts, route comparisons and "stacks". Almost none of them cite anything. This page does the opposite: it sets out what Semax is, what the published research actually measured, how regulators in Australia, the US and Europe treat it, and why a responsible answer to "what dose?" is that no verified one exists for self-use.

What is Semax?

Semax is a synthetic seven-amino-acid peptide (a heptapeptide: Met-Glu-His-Phe-Pro-Gly-Pro). It is built from a fragment of adrenocorticotropic hormone, the pituitary hormone usually shortened to ACTH, with a short tail added to make it last longer. It was developed in Russia, and Russian clinical papers describe it as a domestic drug: a 2000 ophthalmology study calls it a "new Russian drug" given as nasal drops.

Online it is sold as a "nootropic", a loose label for anything claimed to sharpen thinking. That marketing is far ahead of the evidence.

What does the research on Semax actually show?

A PubMed search for "Semax" in titles and abstracts returns roughly 200 records (checked October 2026). Most are rodent or cell studies, and most come from a small number of Russian research groups. The main threads:

• Brain growth factors in rats. A 2006 Journal of Neurochemistry study found intranasal Semax raised brain-derived neurotrophic factor (BDNF, a protein involved in learning and nerve cell survival) in one region of the rat brain within hours. Rodent biology is a starting point, not proof of a benefit in people.
• Stroke rehabilitation. A 2018 Russian study of 110 stroke patients reported higher blood BDNF and better functional scores in those given Semax alongside rehabilitation. The abstract does not describe randomisation or blinding, and the full paper is in Russian.
• Motor neurone disease. An open-label study of 27 patients (2007) found Semax did not change the course of nerve damage or clinical scores, though quality-of-life questionnaires improved. Open-label means everyone knew what they were taking, which inflates self-reported benefits.
• Healthy volunteers. A 2018 brain-imaging study of 24 healthy adults showed changes in resting brain network activity after intranasal Semax versus placebo. It did not measure memory, focus or work performance.

Independent reviewers are blunt about the gap. A 2026 review of therapeutic peptides that discusses Semax concludes that although preclinical studies look promising, "there is a current lack of clinical trials". No large, independent, placebo-controlled trial has shown that Semax improves cognition in healthy people.

Intranasal vs subcutaneous Semax: what is known about each route?

The route question is where online guides are most misleading, because they compare two routes as if both had human data. They do not.

The closest thing to a route comparison is a 2010 rat study comparing intranasal delivery with injection into the abdominal cavity. The two routes produced different effects on learning and pain sensitivity, which the authors read as different mechanisms. That is a reason for caution about switching routes, not a basis for picking one.

Why does this article not give a Semax dose?

Because no dose has been established as safe and effective for self-use anywhere outside Russia's own regulatory system. The amounts used in Russian hospital studies were chosen for specific conditions, in supervised settings, with a domestically regulated product. Transferring them to a healthy person using an unregulated powder makes three unverified leaps at once: different population, different goal, unknown product. On top of that, the actual content of a research vial is not guaranteed to match its label, so any number on a forum chart is attached to an unknown quantity.

Is Semax approved in Australia, the US or the EU?

• Australia. A search of the TGA's Product Information repository returns no documents for Semax (checked 3 October 2026). NSW Health states that "it is unlawful to import, advertise, manufacture and supply unapproved peptide products in Australia", and advises against buying any peptide not prescribed by your usual clinician and supplied through a registered Australian pharmacy.
• United States. The FDA lists Semax among bulk substances it reviewed for potential significant safety risks in compounding, noting possible immune reactions (immunogenicity) from aggregation and peptide impurities, and that it has "no, or limited, safety-related information". The nomination was later withdrawn; the FDA's risk summary remains published.
• European Union. The European Medicines Agency's medicines database lists no authorised medicine containing Semax (data export dated 2 October 2026).

What are the risks of "research use only" Semax?

"Research use only" is a label that shifts responsibility to the buyer. It means the product has not been assessed as a medicine: no verified identity, strength, sterility or stability for human use. In April 2026 the TGA warned health practitioners about unapproved peptides, and newsGP reported the regulator's point that there is no reliable assurance about vial contents, dose accuracy or sterility. NSW Health reports people arriving at emergency departments after using unapproved peptides, with harms including severe allergic reactions and infections.

Those warnings are not specific to Semax, but the logic carries over. A nasal product made outside a regulated facility can carry contaminants. An injectable one adds infection risk and, per the FDA, the chance of immune reactions to impurities.

How should you evaluate a Semax claim?

1. Find the study. If a claim has no citation, treat it as marketing.
2. Check who was studied. Rats, stroke patients and healthy adults are three different questions.
3. Check the design. Randomised, blinded and placebo-controlled beats open-label or uncontrolled.
4. Check the outcome. A change in a blood marker or a brain scan is not the same as better memory or focus.
5. Check the product. Results from a regulated Russian medicine say nothing about the contents of a research vial.
6. Take the decision to a doctor. A GP can look at what is actually driving poor focus and discuss evidence-based options.

What actually helps focus, if Semax is not the answer?

The unglamorous levers have far better evidence. Sleep timing and consistency come first; see the 9 PM sleep protocol. Attention is often lost to the phone before it is lost to biology, which is the argument in is your phone ruining your lift? and the practical setup in deep work focus blocks. If you are reading about other peptides, the same evidence-first approach applies to peptide storage claims and to GHK-Cu.